The surge in GLP-1 prescriptions is transforming obesity and liver disease care but raising new challenges for gastroenterology. Physicians weigh in with concerns over mounting GI side effects — from slowed motility and difficult colonoscopy prep to gallstones and pancreatitis — while long-term risks like nutritional deficiencies or thyroid cancer remain uncertain. Some highlight compounded versions causing severe reactions, while others note GLP-1’s potential in treating MASLD and reducing liver cancer risk. The consensus: these drugs are a breakthrough, but their widespread use demands vigilance, tailored care, and close monitoring.
Keep Reading
Add A Comment